Catherine Bottomley from our Patient Centred Outcomes team attended the 23rd Annual Conference for the International Society for Quality of Life Research in Copenhagen from 19th-22nd October 2016. This year’s conference theme was “Successful strategies for dealing with the challenges in quality of life research”, and featured several themed plenary sessions, oral research presentations and…
The 19th annual symposium of British Oncology Pharmacy Association (http://www.bopawebsite.org/) was held in Manchester from 14-16 October. As usual the agenda was wide-ranging including clinical updates, research and development, clinical care in the community, NHS policy and access to drugs. Amanda Pulfer (Joint Managing Director of pH Associates) discussed how real world data is increasingly…
From Saturday 29th October – Wednesday 2nd November, the International Society for Pharmacoeconimcs and Outcomes Research will take over the Austrian Center Vienna to host their 19th Annual European Congress. Last year’s ISPOR 18th Annual Congress attracted over 5,000 attendees from all over the world, from global leaders, regulators, researchers, payers, patients and policy makers.…
On Friday Amanda Pulfer, Joint Managing Director, is speaking at the British Oncology Pharmacist Association Annual Symposium (being organised by our OPEN Health colleagues in the Succinct Meetings and Events Team). The symposium is being held in Manchester during the NHS, Policy, Access to Drugs stream. The session ‘Utilising Real World Data in Oncology’ will…
Following the pH summit, “The Real World Challenge; Demanding a More Targeted Approach?”, held at the Kings Fund in April 2016, a meeting report has been published in Pharmaceutical Physician. Please follow this link to read.
The UK Prix Galien awards were held in London last night. Reflecting the continued and growing importance of RWE, this year saw the introduction of a new award category for Real World Evidence. Five drugs and their RWE initiatives were shortlisted for this award. Excitingly for pH, of the five, two were for projects…
We are thrilled that two RWE studies which were designed and conducted by pH Associates have been shortlisted for the new Real World Evidence category of the prestigious Prix Galien awards. The studies involved looking at real world outcomes of an antibody used in severe allergic Asthma (Novartis) and a macrocyclic antibiotic (Astellas) and have…
Medicines that are aimed at more and more specific targets, resulting in smaller and smaller groups of patients who can benefit from new drugs, are becoming a familiar story in cancer treatment. Rare diseases by definition also each affect small numbers of patients. But as Professor Richard Barker, Director of CASMI reminded the audience…
Making sure that patients have timely access to effective and safe treatments remains one of our key challenges in the global healthcare system. In a state funded NHS, where resources are limited, the health technology assessment (HTA) process remains the cornerstone of access to new treatments. Here we examine the barriers to patient access of…
A dispatch from the 2016 pH Summit Professor Mehta, Consultant Haematologist at the Royal Free Hospital, likes his football analogies. Back in 2002 when Manchester United parted with an eye-watering £30 million to secure Rio Ferdinand, the NHS were spending the same figure on enzyme replacement therapies (ERT) for rare diseases, such as Fabry and…
